

MAGEA2 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6164a**Specification****MAGEA2 Antibody (N-term) Blocking Peptide - Product Information**

Primary Accession [P43356](#)
Other Accession [NP_005352](#)

MAGEA2 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 266740;4101

Other Names

Melanoma-associated antigen 2,
Cancer/testis antigen 12, CT12, MAGE-2
antigen, MAGEA2, MAGE2, MAGEA2A

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6164a](#) was selected from the N-term region of human MAGEA2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MAGEA2 Antibody (N-term) Blocking Peptide - Protein Information

Name MAGEA2

MAGEA2 Antibody (N-term) Blocking Peptide - Background

MAGEA2 is a member of the MAGEA gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 80% sequence identity between each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are expressed at a high level in a number of tumors of various histologic types, and are silent in normal tissues with the exception of testis and placenta. The MAGEA genes are clustered on chromosome Xq28. They may be implicated in some hereditary disorders, such as dyskeratosis congenita. This gene has two identical copies at different loci.

MAGEA2 Antibody (N-term) Blocking Peptide - References

Rogner, U.C., et al., Genomics 29(3):725-731 (1995). De Smet, C., et al., Immunogenetics 39(2):121-129 (1994). De Plaen, E., et al., Immunogenetics 40(5):360-369 (1994). van der Bruggen, P., et al., Science 254(5038):1643-1647 (1991).

Synonyms MAGE2, MAGEA2A**Function**

Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation.

Cellular Location

Nucleus. Nucleus, PML body.

Tissue Location

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes

MAGEA2 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)